Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier
AssigneeAllergan, Inc.
InventorsJohn T. Trogden, Robert T. Lyons
Life of this patent
Estimating the term…
Abstract
A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.
Claims5
A method for treating an ocular condition associated with neovascularization of the eye in a patient, the method comprising administering an extruded biodegradable intraocular implant to the patient by intravitreal injection, wherein the extruded biodegradable intraocular implant consists of:
- a) about 70-85% by weight of a biodegradable polymeric carrier, wherein the biodegradable polymeric carrier is a poly-lactide-co-glycolide (PLGA);
- b) about 10-20% by weight of an anti-VEGF antibody;
- and
- c) about 5-10% by weight of a saturated straight chain alcohol 16 to 26 carbon atoms in length.
Dependencies are inferred from the claim text.